Table 3. Comparison of clinical characteristics between pCR and non-pCR patients.
| Characteristics | Non-pCR, n (%) | pCR, n (%) | P value |
|---|---|---|---|
| Age | 0.939 | ||
| ≤50 years | 131 (74.9) | 44 (25.1) | |
| >50 years | 64 (75.3) | 21 (24.7) | |
| Menopausal | 1.000 | ||
| Premenopausal | 132 (75.0) | 44 (25.0) | |
| Postmenopausal | 63 (75.0) | 21 (25.0) | |
| Pre-NACT T stage | 0.012 | ||
| T1–2 | 100 (69.0) | 45 (31.0) | |
| T3–4 | 95 (82.6) | 20 (17.4) | |
| Pre-NACT N stage | 0.352 | ||
| N0–1 | 57 (71.3 ) | 23 (28.8) | |
| N2–3 | 138 (76.7) | 42 (23.3) | |
| Pre-NACT TNM stage | 0.545 | ||
| I–II | 41 (71.9) | 16 (28.1) | |
| III | 154 (75.9) | 49 (24.1) | |
| ER | <0.001 | ||
| Negative | 58 (60.4) | 38 (39.6) | |
| Positive | 137 (83.5) | 27 (16.5) | |
| PR | 0.001 | ||
| Negative | 83 (65.9) | 43 (34.1) | |
| Positive | 112 (83.6) | 22 (16.4) | |
| HER2 | 0.001 | ||
| Negative | 123 (82.6) | 26 (17.4) | |
| Positive | 72 (64.9) | 39 (35.1) | |
| Molecular subtype | <0.001 | ||
| TNBC | 25 (62.5) | 15 (37.5) | |
| HER2 positive | 30 (61.2) | 19 (38.8) | |
| Luminal A | 67 (94.4) | 4 (5.6) | |
| Luminal B | 73 (73.0) | 27 (27.0) | |
| AR | 0.526 | ||
| Negative | 16 (88.9) | 2 (11.1) | |
| Positive | 121 (93.1) | 9 (6.9) | |
| Ki-67 | 0.005 | ||
| ≥30% | 95 (69.3) | 42 (30.7) | |
| <30% | 98 (84.5) | 18 (15.5) | |
| Baseline SIII | 0.846 | ||
| ≤376.4 | 32 (76.2) | 10 (23.8) | |
| >376.4 | 163 (74.8) | 55 (25.2) | |
| Baseline NLR | 0.725 | ||
| ≤4.0 | 174 (74.7) | 59 (25.3) | |
| >4.0 | 21 (77.8) | 6 (22.2) | |
| Baseline PLR | 0.191 | ||
| ≤94.1 | 21 (65.6) | 11 (34.4) | |
| >94.1 | 174 (76.3) | 54 (23.7) | |
| Baseline LMR | 0.922 | ||
| <3.0 | 31 (75.6) | 10 (24.4) | |
| ≥3.0 | 164 (74.9) | 55 (25.1) |
pCR, pathological complete response; pre-NACT, pre-neoadjuvant chemotherapy; TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; AR, androgen receptor; SIII, systemic immune inflammation index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio.